<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trimethoprim: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trimethoprim: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trimethoprim: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11894" href="/d/html/11894.html" rel="external">see "Trimethoprim: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12865" href="/d/html/12865.html" rel="external">see "Trimethoprim: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F231470"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Primsol [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F231508"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F231474"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris (alternative agent) (off-label use):</b>
<b>Oral:</b> 100 mg 3 times daily or 300 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17941358','lexi-content-ref-10583139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17941358','lexi-content-ref-10583139'])">Ref</a></span>). The shortest possible duration should be used to minimize development of bacterial resistance; re-evaluate at 3 to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="473eff5c-78ea-4576-a487-f76a5a5e1a73">Pneumocystis pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis</b></i>
<b> pneumonia, treatment (mild to moderate infection) (alternative agent) (off-label use):</b>
<b>Oral:</b> 5 mg/kg every 8 hours in combination with dapsone for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment:</i>
<b>Oral: </b>100 mg every 12 hours for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, prophylaxis for recurrent infection (alternative agent):</i>
<b>Note:</b> May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-Hooton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-Hooton.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous prophylaxis: <b>Oral:</b> 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31042112','lexi-content-ref-6227756','lexi-content-ref-4475571','lexi-content-ref-6992677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31042112','lexi-content-ref-6227756','lexi-content-ref-4475571','lexi-content-ref-6992677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Postcoital prophylaxis (females with cystitis temporally related to sexual intercourse): <b>Oral:</b> 100 mg as a single dose immediately before or after sexual intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2019'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991039"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustments necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 30 mL/minute: Administer 50% of recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Alternate recommendations:</p>
<p style="text-indent:-2em;margin-left:4em;">Aronoff 2007: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 100 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 30 mL/minute: 100 mg every 18 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: 100 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent Hemodialysis: Moderately dialyzable (20% to 59%). Dose after dialysis</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 100 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">HHS (OI adult 2020): <i>Pneumocystis</i> pneumonia, treatment: <b>Note:</b> The following dosage adjustments are based on a usual maintenance dose of 5 mg/kg every 8 hours. Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 30 mL/minute: 5 mg/kg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: 5 mg/kg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent Hemodialysis: Moderately dialyzable (20% to 59%). 5 mg/kg every 24 hours; dose after dialysis on dialysis day.</p></div>
<div class="block doha drugH1Div" id="F50988269"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. </p></div>
<div class="block doe drugH1Div" id="F231475"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F231493"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12865" href="/d/html/12865.html" rel="external">see "Trimethoprim: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute:</b> Infants ≥6 months, Children, and Adolescents: Oral: 10 mg/kg/day in divided doses every 12 hours for 10 days; maximum daily dose: 400 mg/day</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68ea4564-c2b6-429c-8a8b-e8846ecb9178">Urinary tract infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (uncomplicated), treatment:</b> Infants ≥2 months, Children, and Adolescents: Oral: 4 to 6 mg/kg/day in divided doses every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>); <b>Note:</b> Preferred therapy is sulfamethoxazole and trimethoprim combined product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8f01ae1-8bb4-46b0-a53d-24f5962b66de">
<i>Pneumocystis jirovecii</i> pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii</i> pneumonia (PCP), treatment:</b> Children and Adolescents: Oral: 15 mg/kg/day in 3 divided doses for 21 days; in combination with dapsone; data in children is limited; preferred therapy is sulfamethoxazole and trimethoprim combined product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193043"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 30 mL/minute: Administer 50% of recommended dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderately dialyzable (20% to 50%)</p></div>
<div class="block dohp drugH1Div" id="F51193044"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments are provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F231439"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in infants, children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 7%; including maculopapular rash, morbilliform rash, pruritic rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4%), vomiting (2%)</p>
<p style="text-indent:0em;">&lt;1%: Gastrointestinal: Abdominal pain</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Phototoxicity, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Epigastric discomfort, glossitis, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, lymphocytosis, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis (Sood 2021), vasculitis of the skin (Holt 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridium difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice (Singh 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Nordstrand 2004), drug reaction with eosinophilia and systemic symptoms (Subhani 2020), severe hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Mathanasenarajah 2017)</p></div>
<div class="block coi drugH1Div" id="F231454"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to trimethoprim or any component of the formulation; megaloblastic anemia due to folate deficiency</p></div>
<div class="block war drugH1Div" id="F231436"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: May rarely interfere with hematopoiesis, especially with large doses or long term therapy; monitor patients on long term therapy for signs/symptoms of hematologic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: May cause hyperkalemia; potential risk factors include high dosage (20 mg/kg/day), renal impairment, older age, hypoaldosteronism, and concomitant use of medications causing or exacerbating hyperkalemia (Perazella 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions have been reported (rarely).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Elderly patients may be at risk for hyperkalemia with trimethoprim use and are at an increased risk for severe and potentially life-threatening hyperkalemia when trimethoprim is used concomitantly with medications known to cause or exacerbate hyperkalemia, such as spironolactone, ACE inhibitors, or ARBs (Antoniou 2010; Antoniou 2011; Antoniou 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic antiseizure therapy, or elderly).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Otitis media: Not indicated for prophylactic or prolonged administration in otitis media at any age.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878658"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Due to resistance, should not be used for treatment of acute otitis media caused by <i>Moraxella catarrhalis</i>. Trimethoprim is not indicated for prolonged administration or prophylaxis of otitis media in any age. </p></div>
<div class="block foc drugH1Div" id="F231446"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Primsol: 50 mg/5 mL (473 mL [DSC]) [alcohol free, dye free; contains methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium benzoate; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block geq drugH1Div" id="F231432"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F231456"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trimethoprim Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868516"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block adm drugH1Div" id="F231451"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food; may administer with milk or food if GI upset occurs.</p></div>
<div class="block admp drugH1Div" id="F52613977"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach; may administer with milk or food if GI upset occurs</p></div>
<div class="block use drugH1Div" id="F231450"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystitis, acute uncomplicated (tablets, oral solution):</b> Treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Klebsiella pneumoniae</i>, <i>Enterobacter</i> species and coagulase-negative <i>Staphylococcus</i> species, including <i>S. saprophyticus</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (oral solution):</b> Treatment of acute otitis media in pediatric patients due to susceptible strains of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i>.</p></div>
<div class="block off-label drugH1Div" id="F25744928"><span class="drugH1">Use: Off-Label: Adult</span><p>Acne vulgaris; Pneumocystis pneumonia, treatment (mild to moderate infection)</p></div>
<div class="block cyt drugH1Div" id="F231504"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C8 (weak), OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F231441"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus or delirium may be increased. Trimethoprim may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Trimethoprim may enhance the neutropenic effect of Amodiaquine. Trimethoprim may increase the serum concentration of Amodiaquine.  Management: Avoid coadministration of sulfamethoxazole/trimethoprim and amodiaquine in HIV-infected patients when possible due to the possible increased risk for neutropenia. If coadministration is required, monitor closely for neutropenia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Trimethoprim may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Daprodustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Trimethoprim may increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Trimethoprim may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Trimethoprim may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin. Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamiVUDine: Trimethoprim may increase the serum concentration of LamiVUDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: MATE1/2-K Inhibitors may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Trimethoprim.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.  Management: Consider alternatives to trimethoprim-containing regimens to avoid this interaction. If coadministered, monitor for increased procainamide adverse effects (increased QTc) if trimethoprim is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of Trimethoprim.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP2C8 Inhibitors (Weak) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of RifAMPin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: Trimethoprim may decrease the serum concentration of Sapropterin. Specifically, trimethoprim may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: May enhance the neutropenic effect of Trimethoprim. Trimethoprim may increase the serum concentration of Zidovudine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F231457"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Trimethoprim crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Trimethoprim may affect folic acid metabolism; adverse fetal events may be associated with maternal trimethoprim use immediately prior to or during pregnancy (Andersen 2013a; Andersen 2013b; Mølgaard-Nielsen 2012; Sun 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Studies evaluating the effects of trimethoprim administration in pregnancy have also been conducted with Sulfamethoxazole and Trimethoprim (see sulfamethoxazole/trimethoprim monograph for details).</p></div>
<div class="block brc drugH1Div" id="F8774835"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Milk concentrations of trimethoprim are similar to those in the maternal plasma (Reeves 1979). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends caution while using trimethoprim in a breastfeeding female because trimethoprim may interfere with folic acid metabolism. However, single agent trimethoprim is considered to be compatible with breastfeeding when used in usual recommended doses (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Also see the sulfamethoxazole/trimethoprim monograph for additional information.</p></div>
<div class="block dic drugH1Div" id="F231458"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May cause folic acid deficiency, supplements may be needed.</p></div>
<div class="block mop drugH1Div" id="F13493305"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, platelet count, liver enzyme tests, bilirubin, serum potassium, serum creatinine, and BUN periodically during long-term therapy</p></div>
<div class="block pha drugH1Div" id="F231435"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits folic acid reduction to tetrahydrofolate by reversible inhibition of dihydrofolate reductase, inhibiting bacterial synthesis of nucleic acids and proteins</p></div>
<div class="block phk drugH1Div" id="F231453"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Readily and extensively absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely into body tissues and fluids (middle ear, prostate, bile, aqueous humor, CSF); mean peak middle ear fluid concentration in children 1 to 12 years of 2 mcg/mL after a single 4 mg/kg dose; V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Newborns: 2.7 L/kg (range: 1.3 to 4.1 hours) (Springer 1982) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants: 1.5 L/kg (Hoppu 1989) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children (Hoppu 1987): </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">1 to 3 years: 0.86 L/kg </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">8 to 10 years: 1 L/kg </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: ~1.3 L/kg (Hoppu 1987) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~44% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Partially hepatic (10% to 20%) via demethylation, oxidation, and hydroxylation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Similar for tablets and solution </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Prolonged with renal impairment </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Newborns: 19 hours; range: 11 to 27 hours (Springer 1982) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants 2 months to 1 year: 4.6 hours; range: 3 to 6 hours (Hoppu 1989) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children (Hoppu 1987): </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">1 to 3 years: 3.7 hours </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">8 to 10 years: 5.4 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults, normal renal function: 8 to 10 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 1 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine (50% to 60%; 80% as unchanged drug); feces</p></div>
<div class="block phksp drugH1Div" id="F51204411"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038854"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Methostat | Trimol-a</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Motrim | Solotrim | Trimethoprim agepha | Triprim</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alprim | Trimethoprim mylan | Triprim</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Novoprim | Tritrin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Wellcoprim</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Monotrim</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Triprim</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Infectotrimet | Tmp ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Sultrim</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Trimetoprim</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Trimetin | Trimetop | Trimopan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Epirim</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Oratrim | Trimecur | Trimetin | Trimex | Trimfect | Trimopan | Trimro</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Delprim | Wellcoprim</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ipral | Monotrim | Tiempe | Trimethoprim Almus | Trimethoprim arrow | Trimethoprim berk | Trimethoprim cox | Trimethoprim kent | Trimethoprim ntn | Trimogal | Trimopan | Triprimix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ipral | Monotrim | Trimoptin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bacstol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tmp | Trimetin | Trimetop</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Wellcoprim</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Infectotrimet | Tmp ratiopharm | Trimetin | Trimetop | Trimopan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Wellcoprim</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alprim | Uritrim</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Monotrim | Trimethoprim Alpharma | Trimethoprim Sandoz | Trimethoprim teva | Wellcoprim</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Trimetoprim | Trimetoprim gea</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tmp</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Syraprim</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Trimesan | Urotrim</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Proloprim | Trimpex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Trimopan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trimidar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Idotrim | Trimetoprim astrazeneca | Trimetoprim meda | Trimopan | Wellcoprim</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alprim</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Triprim</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Syraprim | Trimethop</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bactin | Catin | Eumi | Giprim | Inflamnil | Lanprim | Meprim | Metipine | Motrim | Panmitin | Thi Fen | Trimcort | Trimprim | Triprim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Trimethprim</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17941358">
<a name="17941358"></a>Amin K, Riddle CC, Aires DJ, Schweiger ES. Common and alternate oral antibiotic therapies for acne vulgaris: a review.<i> J Drugs Dermatol</i>. 2007;6(9):873-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/17941358/pubmed" id="17941358" target="_blank">17941358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010291">
<a name="23010291"></a>Andersen JT, Petersen M, Jimenez-Solem E, et al. Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study. <i>Epidemiol Infect.</i> 2013a;141(8):1749-1755.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/23010291/pubmed" id="23010291" target="_blank">23010291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23476656">
<a name="23476656"></a>Andersen JT, Petersen M, Jimenez-Solem E, et al. Trimethoprim use prior to pregnancy and the risk of congenital malformation: a register-based nationwide cohort study. <i>Obstet Gynecol Int.</i> 2013b;2013:364526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/23476656/pubmed" id="23476656" target="_blank">23476656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31042112">
<a name="31042112"></a>Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. <i>J Urol</i>. 2019;202(2):282-289. doi:10.1097/JU.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/31042112/pubmed" id="31042112" target="_blank">31042112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21911446">
<a name="21911446"></a>Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/21911446/pubmed" id="21911446" target="_blank">21911446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25646289">
<a name="25646289"></a>Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015;187(4):E138-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/25646289/pubmed" id="25646289" target="_blank">25646289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8219422">
<a name="8219422"></a>Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. <i>Dermatology</i>. 1993;187(3):193-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/8219422/pubmed" id="8219422" target="_blank">8219422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6227756">
<a name="6227756"></a>Brumfitt W, Hamilton-Miller JM, Gargan RA, Cooper J, Smith GW. Long-term prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidone-iodine. <i>J Urol</i>. 1983;130(6):1110-1114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/6227756/pubmed" id="6227756" target="_blank">6227756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10583139">
<a name="10583139"></a>Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. <i>Br J Dermatol</i>. 1999;141(4):757-758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/10583139/pubmed" id="10583139" target="_blank">10583139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6213255">
<a name="6213255"></a>Gibson JR, Darley CR, Harvey SG, Barth J. Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris. <i>Br J Dermatol</i>. 1982;107(2):221-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/6213255/pubmed" id="6213255" target="_blank">6213255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2019">
<a name="Hooton.2019"></a>Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1630995">
<a name="1630995"></a>Holt RI, Ebrahim SB. Trimethoprim-induced vasculitis. <i>Postgrad Med J</i>. 1992;68(799):391. doi:10.1136/pgmj.68.799.391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/1630995/pubmed" id="1630995" target="_blank">1630995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3816021">
<a name="3816021"></a>Hoppu K, “Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children?” <i>Clin Pharmacol Ther</i>, 1987, 41(3):336-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/3816021/pubmed" id="3816021" target="_blank">3816021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2705795">
<a name="2705795"></a>Hoppu K. Changes in Trimethoprim Pharmacokinetics After the Newborn Period. <i>Arch Dis Child. </i>1989;64(3):343-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/2705795/pubmed" id="2705795" target="_blank">2705795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4475571">
<a name="4475571"></a>Kasanen A, Kaarsalo E, Hiltunen R, Soini V. Comparison of long-term, low-dosage nitrofurantoin, methenamine hippurate, trimethoprim and trimethoprim-sulphamethoxazole on the control of recurrent urinary tract infection. <i>Ann of Clin Research</i>. 1974;6(5):285-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/4475571/pubmed" id="4475571" target="_blank">4475571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842992">
<a name="20842992"></a>Kodner CM and Thomas Gupton EK, “Recurrent Urinary Tract Infections in Women: Diagnosis and Management,” <i>Am Fam Physician</i>, 2010, 82(6):638-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/20842992/pubmed" id="20842992" target="_blank">20842992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18556490">
<a name="18556490"></a>Lee M, Bozzo P, Einarson A, et al, "Urinary Tract Infections in Pregnancy," <i>Can Fam Physician</i>, 2008, 54(6):853-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/18556490/pubmed" id="18556490" target="_blank">18556490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26585421">
<a name="26585421"></a>Mathanasenarajah G, Hoi A. Trimethoprim-induced aseptic meningitis: a reminder case review. <i>Int J Rheum Dis</i>. 2017;20(5):664-665. doi:10.1111/1756-185X.12798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/26585421/pubmed" id="26585421" target="_blank">26585421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22125260">
<a name="22125260"></a>Mølgaard-Nielsen D, Hviid A. Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort study. <i>Pharmacoepidemiol Drug Saf</i>. 2012;21(3):246-253. doi: 10.1002/pds.2179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/22125260/pubmed" id="22125260" target="_blank">22125260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15714408">
<a name="15714408"></a>Nicolle LE, Bradley S, Colgan R, et al, "Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults," <i>Clin Infect Dis</i>, 2005, 40(5):643-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/15714408/pubmed" id="15714408" target="_blank">15714408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15239760">
<a name="15239760"></a>Nordstrand IA. Anaphylaxis to trimethoprim: an under-appreciated risk in acute medical care. <i>Emerg Med Australas</i>. 2004;16(1):82-85. doi:10.1111/j.1742-6723.2004.00546.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/15239760/pubmed" id="15239760" target="_blank">15239760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10738846">
<a name="10738846"></a>Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. <i>Drug Saf</i>. 2000;22(3):227-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/10738846/pubmed" id="10738846" target="_blank">10738846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Primsol.1">
<a name="Primsol.1"></a>Primsol Solution (trimethoprim) oral solution [prescribing information]. Englewood, CO: Aytu Pharmaceuticals; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-389810">
<a name="389810"></a>Reeves DS and Wilkinson PJ, "The Pharmacokinetics of Trimethoprim and Trimethoprim/Sulphonamide Combinations, Including Penetration Into Body Tissues,"<i> Infection</i>, 1979, 7(Suppl 4):S330-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/389810/pubmed" id="389810" target="_blank">389810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1137830">
<a name="1137830"></a>Reid DW, Caille G, and Kaufmann NR, "Maternal and Transplacental Kinetics of Trimethoprim and Sulfamethoxazole, Separately and in Combination," <i>Can Med Assoc J</i>, 1975, 112(13 Spec No):67-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/1137830/pubmed" id="1137830" target="_blank">1137830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schleiss.1">
<a name="Schleiss.1"></a>Schleiss MR. Principles of Antibacterial Therapy. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Kliegman RM, Stanton BF, St Geme JW, and Schor NF, eds. Philadelphia, PA: Elsevier, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1937651">
<a name="1937651"></a>Singh UK, Singh VK. Cholestatic jaundice caused by trimethoprim. <i>Indian J Pediatr</i>. 1991;58(3):373-375. doi:10.1007/BF02754972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/1937651/pubmed" id="1937651" target="_blank">1937651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33948423">
<a name="33948423"></a>Sood M, Oyibo SO, Rajkanna J. A case of toxic epidermal necrolysis caused by the use of trimethoprim alone. <i>Cureus</i>. 2021;13(4):e14783. doi:10.7759/cureus.14783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/33948423/pubmed" id="33948423" target="_blank">33948423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7062219">
<a name="7062219"></a>Springer C, Eyal F, and Michel J, "Pharmacology of Trimethoprim-Sulfamethoxazole in Newborn Infants," <i>J Pediatr</i>, 1982, 100(4):647-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/7062219/pubmed" id="7062219" target="_blank">7062219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6992677">
<a name="6992677"></a>Stamm WE, Counts GW, Wagner KF, et al. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. <i>Ann of Int Med</i>. 1980;92(6):770-775.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/6992677/pubmed" id="6992677" target="_blank">6992677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33363781">
<a name="33363781"></a>Subhani M, Dong V, Connolly A, et al. Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpes virus-6 (HHV-6) leading to acute liver failure. <i>Clin Case Rep</i>. 2020;8(12):2568-2573. doi:10.1002/ccr3.3218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/33363781/pubmed" id="33363781" target="_blank">33363781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25111783">
<a name="25111783"></a>Sun Y, Wu CS, Olsen J. Trimethoprim use before pregnancy and risk of congenital malformation: reanalyzed using a case-crossover design and a case-time-control design. <i>Pharmacoepidemiol Drug Saf</i>. 2014;23(10):1076-1083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/25111783/pubmed" id="25111783" target="_blank">25111783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mayne.1">
<a name="Mayne.1"></a>Trimethoprim tablets [prescribing information]. Greenville, NC: Mayne Pharma; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trimpex.1">
<a name="Trimpex.1"></a>Trimpex (trimethoprim) [prescribing information]. Flowood, MS: Key Therapeutics; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. November 2013. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol</i>. 2016;74(5):945-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trimethoprim-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10024 Version 307.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
